Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.

Despite a U.S. factory mixup, more Johnson & Johnson doses are becoming available in the U.S., marking the only single-shot vaccine option. So how effective is it and how does it compare to the Pfizer ...

Both Moderna MRNA and BioNTech BNTX are leading biotechs at the forefront of messenger RNA (mRNA) technology. The companies rose to prominence with their respective COVID-19 vaccines, but their ...

Moderna is suing its chief competitor in the COVID-19 vaccine space, alleging that Pfizer and BioNTech stole key technology used in the development of that group's inoculation. Both Moderna and the ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna’s EP’949 patent. This decision affirms the ...

LNPs have been a frequent point of contention in the mire of patent litigation that has sprung up around mRNA vaccine technology following the approvals of Pfizer’s and Moderna’s products. (iStock / ...

A vial of the Moderna Covid-19 vaccine and syringes sit prepared at a pop up vaccine clinic at the Jewish Community Center on April 16, 2021 in the Staten Island borough of New York City. Moderna is ...